Azienda Unita Sanitaria Locale Di Bologna
Bologna, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This study is looking at a condition called Narcolepsy without Cataplexy, also known as NT2. This is a sleep disorder where people experience excessive daytime sleepiness and may suddenly fall asleep during the day, but they do not have sudden muscle weakness or loss of muscle control that can occur in other forms of narcolepsy. The treatment being tested is called TAK-360, which is an experimental medication given as a tablet by mouth. Some participants will receive TAK-360 while others will receive placebo. The purpose of this study is to evaluate the safety and tolerability of TAK-360.
During the study, participants will take TAK-360 or placebo for a period of 4 weeks. The study will look at whether any unwanted effects occur during treatment. The study will also measure changes in daytime sleepiness using a questionnaire called the Epworth Sleepiness Scale, which asks about how likely someone is to fall asleep in different situations. Additionally, a test called the Maintenance of Wakefulness Test will be used, which measures how well someone can stay awake in a quiet, comfortable setting. These measurements will be compared between the group taking TAK-360 and the group taking placebo to see if there are any differences.
Participants in this study will be adults between 18 and 70 years old who have been diagnosed with NT2. The study uses a design where neither the participants nor the doctors know who is receiving the actual medication and who is receiving placebo until the study is completed. This helps ensure that the results are measured fairly and without bias. The study will continue for several weeks and will involve regular visits to check on safety and how well the treatment is working.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
4 criteria
3 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Bologna, Italy
Verona, Italy
Clichy, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an investigational medication being studied for the treatment of narcolepsy without cataplexy. This is an experimental drug that is being tested to see if it is safe and effective for people who have narcolepsy but do not experience cataplexy, which is a sudden loss of muscle control. The trial will look at different amounts of this medication to find the best dose that works well and is safe for patients to take.
is an inactive substance that looks like the real medication but contains no active treatment. It is used in this study to compare against TAK-360 to help researchers understand if the actual medication is working better than no treatment at all.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.